Coming soon

Ask REGTEKA AI is on its way.

Ask regulatory questions across REGTEKA intelligence.

Hear when it launches: the Regulatory Briefing

For Physicians

Regulatory decisions,
read for the clinic.

New approvals. New devices. Safety actions. What the evidence shows,
who it affects, and what changes at the point of care.

  • VerifiedChecked against the regulator’s record
  • ClinicalThe evidence, the label, the practice impact
  • By specialty36 specialties, searchable
A physician in a white coat reads a patient chart while walking a hospital corridor

What changed.
Who it affects.
What to do.

Evidence. Access. Practice.

For Physicians

Physician Home

Advertise with us Sponsored placements, clearly labeled and separate from the analysis.

48 physician stories Updated November 5, 2026

For Physicians Two researchers in lab coats and safety glasses review documents in a clinical research corridor NeurologyNeurosurgeryFDA FDA Accepts First Gene Therapy for Huntington’s FDA accepted uniQure’s Biologics License Application for AMT-130 (ifezuntirgene inilparvovec) on 2 November 2026, granting Priority Review under the Accelerated Approval pathway with a target action date of 1 May 2027. It would be the first disease-modifying treatment ever approved for Huntington’s disease — but the trial data behind it have told three different stories in the past 14 months, and the newest one lost statistical significance. Nov 5, 2026Read the story For Physicians A physician in a white coat talks with a patient across a desk with pill bottles between them OncologyUrologyPathologyFDA FDA Moves a Targeted Combo Earlier in Prostate Cancer FDA approved Pfizer’s Talzenna (talazoparib) plus Xtandi (enzalutamide) on 26 October 2026 for HRR gene-mutated metastatic hormone-sensitive prostate cancer — moving a genomically matched PARP inhibitor from last-line, castration-resistant disease to the point of diagnosis. The catch: a 52% drop in progression risk comes with grade 3 anemia in half of patients, in a population that will likely stay on treatment for years, not months. Nov 2, 2026Read the story For Physicians A professional reviews information on a laptop, a generic stand-in for a clinician reviewing updated product labeling OB/GYNFamily MedicineInternal MedicineFDA FDA Narrows Menopause Hormone Therapy’s Boxed Warning FDA removed cardiovascular-disease, breast-cancer and “probable dementia” boxed-warning language from three more estradiol patches on October 30, 2026 — the second round of a rollback that now covers nine products. The agency won’t say which three patches changed, and a dispute over the science behind the whole rollback is now playing out in JAMA between FDA leadership and former Women’s Health Initiative safety monitors. Nov 1, 2026Read the story For Physicians A clinician ties a blue surgical gown in a clinical setting, a generic pre-procedure stand-in HematologyPediatricsMHRA MHRA Lowers Casgevy’s Age Floor to Five; FDA’s Is Two MHRA has widened Casgevy (exagamglogene autotemcel) to children as young as five with severe sickle-cell disease or transfusion-dependent beta-thalassemia — built on direct trial evidence in that age band, not extrapolation. The FDA's own floor is two, reached a different way. What a hematologist needs before counselling a family with a newly eligible child, including a fertility-preservation question that has nothing to do with either regulator. Oct 31, 2026Read the story For Physicians A sunlit colonnade of classical columns, used as a generic regulatory-decision backdrop Otolaryngology (ENT)FDA FDA Approves Voceryq, a DNA Immunotherapy for RRP Voceryq (INO-3107) is Inovio's first FDA-approved product and only the second approved therapy for recurrent respiratory papillomatosis — a plasmid DNA immunotherapy against HPV-6/11, cleared on early, single-arm evidence. What it changes for the otolaryngologist managing a patient on the surgical treadmill, and where it leaves Papzimeos, the drug already on the market. Oct 31, 2026Read the story For Physicians A clinician examines a patient's skin near the hairline in a clinic, a generic stand-in for a skin check DermatologyRheumatologyMHRAFDA UK Clears Oral Psoriasis Pill Already Used in US MHRA’s 23 October approval of icotrokinra (Icotyde) makes the UK the third major market — after the United States in March and the European Union in September — to clear the first oral IL-23 receptor blocker for plaque psoriasis. For dermatologists already prescribing it, and rheumatologists whose patients ask about it, the more useful news arrived alongside: head-to-head trial data against deucravacitinib that puts an actual number on how the two oral options compare. Oct 30, 2026Read the story For Physicians A clinician reviews an anatomical illustration on a tablet with a patient, a generic stand-in for a clinic counseling visit PediatricsOrthopedic SurgeryEMA & EU CHMP Backs Second Achondroplasia Drug, Dosed Weekly The EMA’s human-medicines committee has recommended EU marketing authorization for once-weekly navepegritide (Yuviwel), only the second approved achondroplasia therapy after BioMarin’s daily-dosed Voxzogo. The drug has been available in the United States since April on an accelerated approval. For pediatricians, geneticists and pediatric orthopedists, the practical questions are what the weekly schedule actually buys a family, what the trial proved and didn’t, and whether a patient doing well on the existing option has any reason to move. Oct 29, 2026Read the story For Physicians A clinician in scrubs with a stethoscope, a generic stand-in for a pediatric endocrinologist or primary care physician PediatricsEndocrinologyFDA FDA Extends Once-Weekly Awiqli to Pediatric T2D Novo Nordisk’s weekly basal insulin icodec is now labeled for patients as young as 10 with type 2 diabetes — two years after the same drug was turned away for type 1 diabetes over a hypoglycemia signal. What the pediatric evidence actually covers, and where a 196-hour half-life changes the bedside math. Oct 28, 2026Read the story For Physicians A professional on a desk phone, a generic stand-in for a clinician or pharmacist fielding a prescription question OB/GYNFamily MedicineFDA FDA Approves First Generic Combined Menopause Patch Zydus’s generic of Bayer’s Climara Pro — a once-weekly estradiol-and-levonorgestrel combination patch — is the first competition a roughly $46 million-a-year product has ever had. It arrives as FDA's boxed-warning overhaul for menopausal hormone therapy is still working its way through individual product labels, not as a finished rewrite. Oct 28, 2026Read the story For Physicians Edwards rendering of two PASCAL transcatheter repair implants with paddles and clasps open CardiologyCardiothoracic SurgeryFDA FDA Approves Second Device for Tricuspid Repair FDA approved Edwards Lifesciences’ Pascal Precision system for transcatheter tricuspid edge-to-edge repair (T-TEER) on October 21, 2026 — the second T-TEER device on the U.S. market after Abbott’s TriClip, and the first time a structural heart program has had to choose between two. The randomized trial behind the approval has not yet reported its own results. Oct 27, 2026Read the story For Physicians A smiling executive in a white blazer at an office desk, a generic stand-in for a BioCryst commercial announcement Allergy & ImmunologyPediatricsFDA FDA Extends Orladeyo Pellets to Teens, Adults With HAE BioCryst's oral-pellet formulation of berotralstat (Orladeyo), already approved for children as young as two, is now labeled for the 12-and-older population that could already take the capsule — an administration-route expansion for patients who struggle to swallow it, built on manufacturing data and a safety comparison to the capsule, not a new efficacy trial. Oct 26, 2026Read the story For Physicians Three physicians in white coats review a patient's chart and medication together at a desk Infectious DiseaseGastroenterologyFDA FDA Approves Hibsago, First Antisense Hepatitis B Drug Bepirovirsen (Hibsago) is the first antisense oligonucleotide cleared for chronic hepatitis B — a finite, 24-week add-on that let 19% of a defined, stable patient population stop all treatment and stay virus-free, against 0% on placebo. A companion diagnostic decides who qualifies, and a boxed warning for hepatic flares and thrombocytopenia will shape how it gets prescribed. Oct 26, 2026Read the story For Physicians A physician in a white coat with a stethoscope, a generic stand-in for a vascular surgeon or interventional radiologist Vascular SurgeryRadiologyFDA FDA Clears Lightning CAVT for Deep Vein Thrombosis Penumbra's vacuum thrombectomy platform now carries a dedicated FDA clearance for DVT, on a 229-patient single-arm trial. The company calls it the first cleared DVT indication among mechanical thrombectomy devices — a claim that sits awkwardly next to two devices already labeled for DVT since 2015 and 2020. What actually changed, and who the trial's own criteria say is a candidate. Oct 25, 2026Read the story For Physicians A confident executive in a bright office, a generic stand-in for AstraZeneca/Alexion leadership NephrologyFDA Ultomiris Cleared for IgAN; Kidney Benefit Still Unproven Ravulizumab becomes the first and only C5 complement inhibitor approved for IgA nephropathy — on an accelerated pathway, added on top of maximized background therapy, with a 43.4 percent placebo-adjusted cut in proteinuria at week 34 carrying the filing. Whether it actually slows the loss of kidney function is a question the confirmatory trial won't answer until 2028. Where it fits next to Fabhalta and Filspari, and what the infusion schedule and meningococcal warning mean for a nephrology practice. Oct 25, 2026Read the story For Physicians A senior executive in a dark blouse standing by wood shelving, a generic stand-in for AbbVie leadership GastroenterologyFDA FDA Approves Subcutaneous-Only Skyrizi Induction FDA approved a fully subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) in Crohn’s disease on October 23, 2026 — letting patients start and maintain treatment entirely by injection, four years after the drug’s original approval required three infusion-chair visits to begin. Oct 24, 2026Read the story For Physicians A lab technician in a hairnet and gloves pipetting samples at a bright laboratory bench OncologyPathologyFDA FDA Narrows Pembrolizumab’s TMB-High Cancer Approval The agency converted Keytruda’s 2020 accelerated approval for tumor mutational burden–high solid tumors to full approval on October 16 — but only after raising the biomarker cutoff from 10 to 13 mutations per megabase. Patients who qualified under the old threshold may no longer meet the label. Oct 23, 2026Read the story For Physicians A smiling executive in a pink jacket at a city office window, standing in for SimBioSys's leadership announcing the TumorSight Risk clearance OncologyRadiologyPathologyFDA FDA Clears AI Tool to Score Breast Cancer Recurrence FDA cleared SimBioSys’ TumorSight Risk on 25 September 2026, an AI tool that scores breast-cancer recurrence from an MRI already in the chart — no new biopsy. It enters a decision oncologists already make with tissue-based assays like Oncotype DX, but without the one thing those assays have and TumorSight Risk doesn’t yet: a trial tying the score to who actually benefits from chemotherapy. Oct 21, 2026Read the story For Physicians A smiling physician in a dark suit, standing in for GSK's leadership announcing the Jemperli rectal cancer approval OncologyGeneral SurgeryGastroenterologyFDA FDA Approves First Immunotherapy for Rectal Cancer FDA granted accelerated approval to dostarlimab (Jemperli, GSK) on 19 October 2026 for stage II/III dMMR or MSI-H locally advanced rectal cancer. The drug didn’t approve skipping surgery — but for the patients who reach a complete response, it puts that question on the table for the first time. Oct 21, 2026Read the story For Physicians An ophthalmologist examines an adult patient's eye at a slit lamp during a clinic visit OphthalmologyEndocrinologyFDA FDA Approves Enspryng, First At-Home Thyroid Eye Drug Satralizumab-mwge (Enspryng) is now approved as the first subcutaneous treatment for thyroid eye disease a patient can inject at home, challenging two infused biologics already on the market. One of its two pivotal trials missed its primary endpoint. What changes for the ophthalmologist and endocrinologist co-managing a Graves’ patient. Oct 19, 2026Read the story For Physicians A researcher in a lab coat and face shield uses a pipette with blue reagent, standing in for small-molecule drug research OncologyFDAEMA & EU EMA Recommends First RAS Inhibitor for Pancreatic Cancer EMA’s CHMP has recommended EU approval of Rasonque (daraxonrasib), an oral pan-RAS(ON) inhibitor already available in the US since August 2026 — the first RAS-targeted therapy to reach patients with pancreatic cancer, a disease where more than 90% of tumors carry a RAS mutation. What the evidence shows, what the toxicities mean day to day, and what is and isn’t available yet. Oct 17, 2026Read the story For Physicians A healthcare professional in business attire, standing in for the regulatory and clinical affairs response to an FDA device alert CardiologyCardiothoracic SurgeryFDA FDA Flags Edwards SAPIEN M3 Delivery System After Death FDA posted an early alert on 15 October 2026 after Edwards Lifesciences told customers to remove and return four lots of the Commander M delivery system used to implant its SAPIEN M3 transcatheter mitral valve, following three reports of the delivery balloon bursting during inflation — one fatal, one a serious injury. The valve itself is not implicated. What structural heart programs should check this week. Oct 16, 2026Read the story For Physicians A smiling professional in a blue suit poses for a studio portrait PediatricsPsychiatryFDA FDA Clears Neurora AI Tool for Autism Diagnosis Argus Cognitive’s Neurora is the third FDA-cleared AI tool to score a child’s autism evaluation, after Cognoa’s Canvas Dx and EarliTec’s EarliPoint — and the first of the three to clear without a single published sensitivity, specificity or validation-study figure. What a pediatrician or child psychiatrist should weigh before trusting its score. Oct 14, 2026Read the story For Physicians A business professional smiles while working at a laptop in a sunlit office CardiologyFDA FDA Clears Patient App for Abbott’s CardioMEMS Monitor FDA approved two new software features for Abbott’s CardioMEMS HF System on 5 October 2026: a CardioGuide HF app that lets patients see their own pulmonary artery pressure readings, and a Dynamic Treatment Plan that lets clinicians push protocol-based medication instructions straight to a patient’s phone. The implant and its candidacy criteria do not change — what changes is how an already-implanted population is titrated between visits. Oct 13, 2026Read the story For Physicians A physician in professional attire in a clinical office setting OncologyFDA FDA Adds Tucatinib to HER2+ Breast Cancer Maintenance FDA approved Pfizer’s tucatinib (Tukysa), added to ongoing trastuzumab and pertuzumab, as maintenance therapy for HER2-positive breast cancer patients who have not progressed after induction chemotherapy. In the 654-patient HER2CLIMB-05 trial, the triplet extended median progression-free survival by 8.6 months over maintenance without it — while a hepatotoxicity boxed warning now applies to a less sick patient population, and overall survival data remain immature. Oct 12, 2026Read the story For Physicians A clinician and patient smile together during an eye exam, with an eye-anatomy chart and slit lamp in the background OphthalmologyFDA FDA Approves First Spiral-Optic Presbyopia Lens RayOne Galaxy and RayOne Galaxy Toric trade the concentric diffractive rings of a trifocal lens for a continuous spiral optic, aiming at the same full range of vision with less reported glare and halo. FDA approved both September 24, 2026 on a 250-patient U.S. trial; here is where a non-diffractive design fits among the premium IOLs already on the shelf. Oct 11, 2026Read the story For Physicians A clinician in scrubs at a clinic entrance Preventive MedicineFamily MedicineInfectious Disease NY Declares Measles Emergency, Widens Who Can Vaccinate Governor Hochul's 5 October executive order expands which professionals may give MMR as New York's rural outbreak reaches 108 cases, against a national count already at a 35-year high. What changed in who can vaccinate, and the coverage numbers that explain why this outbreak is spreading. Oct 10, 2026Read the story For Physicians A gowned, masked clinician reviews a chart on a clipboard in a clinical setting AnesthesiologyPsychiatryFDA Brevital Recall Hits an OR and ECT Anesthesia Drug Par Health is recalling two lots of Brevital Sodium (methohexital), used to induce general anesthesia and, in psychiatry, to induce seizures for electroconvulsive therapy, after cellulose particulate turned up in vials. It is the company's second sterile-injectables recall in three weeks. What to quarantine, and how the induction alternatives differ for ECT. Oct 10, 2026Read the story For Physicians A smiling physician in a white coat and glasses, in a plain studio setting OncologyGastroenterologyPathologyFDA FDA Approves First Adjuvant Immunotherapy for Colon Cancer Atezolizumab (Tecentriq) added to oxaliplatin-based chemotherapy is now approved for resected stage III colon cancer that is mismatch-repair deficient or microsatellite instability-high — the first immunotherapy ever approved in colon cancer's curative, rather than metastatic, setting. The ATOMIC trial cut three-year recurrence risk nearly in half, at the cost of more toxicity in patients who would otherwise already be free of disease. Oct 9, 2026Read the story For Physicians A man closely examines a small white electronic medical device held in both hands OncologyGastroenterologyGeneral SurgeryFDA TTFields Device Now Part of Pancreatic Cancer Care Optune Pax, Novocure’s wearable Tumor Treating Fields device, has been FDA-approved since February 2026 for locally advanced pancreatic cancer and reached Japan on 1 October 2026. For an oncologist weighing it against gemcitabine and nab-paclitaxel alone, the trial evidence, the adherence demands, and the comparison to FOLFIRINOX this device was never tested against. Oct 8, 2026Read the story For Physicians A physician in a white coat reviews information on a tablet OncologyPalliative MedicineGastroenterologyMHRA MHRA Approves First Drug for Malignant Ascites Catumaxomab, branded Korjuny, is the only drug ever authorised anywhere specifically for malignant ascites — not the cancer causing it. MHRA cleared it for EpCAM-positive tumours on 7 October 2026. What the pivotal trial actually measured, what the four-infusion regimen asks of a ward, and why it changes nothing yet for a patient in the United States. Oct 8, 2026Read the story For Physicians A physician in a white coat positions a patient at the entrance of an MRI scanner RadiologyGastroenterologyEndocrinologyFDA FDA Clears AI to Quantify Liver, Visceral Fat on MRI AIRS Medical’s SwiftSight Body Composition turns a single MRI sequence — many of them self-pay preventive scans — into a quantified visceral-fat, muscle and liver-fat report. It is the first FDA clearance of its kind to reach patients chiefly through a self-pay longevity-imaging network rather than a physician’s order, with no established reimbursement and no society recommendation to screen for it this way. Oct 7, 2026Read the story For Physicians Two colleagues shake hands in a bright office Infectious DiseasePathologyEmergency MedicineFDA FDA-Cleared Sepsis Panel Now Flags Resistance Genes FDA cleared QIAGEN’s QIAstat-Dx BCID GN Plus AMR Panel on 24 September 2026, completing a gram-negative-plus-resistance-gene menu that returns results from a positive blood culture in about an hour. What the independent evidence says about trusting a genetic resistance call, and where it still needs a culture to confirm. Oct 6, 2026Read the story For Physicians A physician in a white coat reviews a folder while smiling CardiologyPediatricsCardiothoracic SurgeryFDA FDA’s Camzyos Teen Label Requires CYP2C19 Testing FDA's 30 September 2026 approval of Camzyos (mavacamten) for adolescents with symptomatic obstructive HCM made headlines as the first pediatric drug therapy for the disease. The label detail that actually determines the first prescription is a genetic test: CYP2C19 metabolizer status, required before the first dose, with a dose cut for poor metabolizers that general cardiology practices may not be set up to manage. Related: FDA Approves Camzyos for Teens With Obstructive HCM. Oct 5, 2026Read the story For Physicians A physician in a white coat reviews a patient's chart on a clipboard HematologyOncologyFDA FDA Approves Jaypirca for Frontline CLL/SLL Pirtobrutinib (Jaypirca) is now approved as initial therapy for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without a 17p deletion — the first non-covalent BTK inhibitor to reach the frontline setting. BRUIN CLL-313 showed an 80% reduction in the hazard of progression or death against chemoimmunotherapy. What it does not yet show is how it stacks up against the BTK inhibitors already used first-line. Oct 5, 2026Read the story For Physicians A clinician reviews notes with an older patient during a home consultation NeurologyGeriatric MedicineFDA FDA Approves Juvmo, First D1/D5 Agonist for Parkinson’s Tavapadon is a mechanistically new option after decades of D2/D3-selective dopamine agonists — cleared both as monotherapy in early Parkinson’s disease and as an add-on to levodopa for motor fluctuations. The three placebo-controlled TEMPO trials show it works; they do not show it works better than what prescribers already have. Oct 4, 2026Read the story For Physicians A scientist examines a sample under a microscope in a bright laboratory OncologyPulmonologyFDA Daiichi Sankyo, Merck Pull Lung Cancer ADC Filing Ifinatamab deruxtecan would have been the first B7-H3-directed antibody-drug conjugate for small-cell lung cancer. The companies pulled the filing after FDA signaled the Phase 2 data fell short of the accelerated-approval bar — three months after a fatal lung-toxicity signal paused the confirmatory trial. What it means for a disease with few second-line options. Oct 4, 2026Read the story For Physicians A physician in a white coat consults with a patient across a desk in a bright clinic office Cardiothoracic SurgeryPediatricsCardiologyFDA FDA Approves First Expandable Pulmonary Valve for Kids The AUTUS valve is the first pulmonary valve built to be widened in place as a child grows, instead of being removed and replaced in another open-heart operation. It is also the first FDA-approved heart valve with synthetic leaflets rather than animal tissue. What a 62-child pivotal trial showed, and what it does not yet answer. Oct 2, 2026Read the story For Physicians A clinician in a grey blazer reviews a tablet in a bright glass corridor CardiologyInternal MedicineFamily MedicineFDA FDA Clears Tempus AI Tool to Flag Mitral Regurgitation ECG-MR reads a standard 12-lead ECG for patterns associated with undiagnosed moderate or severe mitral regurgitation — Tempus AI's fourth cleared ECG-AI product. It is a flag for an echo referral, not a diagnosis, and its own validation numbers are not yet public. Sep 30, 2026Read the story For Physicians A clinician in a white blouse reviews notes on a tablet in a bright office atrium OncologyGastroenterologyOphthalmologyFDA FDA Approves Lyrfigtu, Third FGFR2 Drug for Bile Duct Cancer Lirafugratinib (Lyrfigtu) is now FDA-approved for previously treated, FGFR2-altered cholangiocarcinoma — a selective, covalent FGFR2 inhibitor entering a field that has already lost one competitor to a withdrawn approval. What its 46% response rate adds, and what its retinal-toxicity monitoring requires. Sep 30, 2026Read the story For Physicians A professional reviews paperwork from an orange folder at a desk CardiologyCardiothoracic Surgery CMS Ends TAVR’s Mandatory Two-Operator Rule CMS finalized an updated national coverage determination for transcatheter aortic valve replacement that lets a single qualified operator perform the procedure and drops hospital volume minimums for existing programs — while keeping the requirement that a hospital have on-site cardiac surgery to offer TAVR at all. Sep 29, 2026Read the story For Physicians A professional reviews a printed binder of documents, page by page Orthopedic SurgeryNeurosurgeryFDA FDA Clears SI-BONE Implant for Fusion Screw Loosening SI-BONE’s iFuse Granite Onyx targets the two screws most likely to loosen in a spinal fusion construct when bone is weak. The clearance rests on bench testing, not a clinical trial — and the only surgeons SI-BONE quotes on it are paid consultants with royalty interests in the device. Sep 29, 2026Read the story For Physicians A professional in a white blouse signs and stamps documents at a desk beside a laptop NeurologyPediatricsFDA FAYUVI’s Label Limits It to Early-Stage Sanfilippo FAYUVI (rebisufligene etisparvovec-hopf, Ultragenyx), approved 17 September as the first treatment for Sanfilippo syndrome type A, is a single infusion priced at $3.95 million — and one that only works before the disease's neurodegeneration takes hold. For a fatal, progressive condition with no prior treatment at all, the regulatory news is straightforward — Regulatory News covered the approval itself the day it happened. What it demands of a referring physician — recognizing the disease early enough for a child to still qualify — is not. Sep 28, 2026Read the story For Physicians A physician in a white coat and scrubs writes in a notebook beside a stethoscope and a tablet NephrologyPediatricsFDA FDA Approves First Drug for Relapsing Nephrotic Syndrome Obinutuzumab (Gazyva, Genentech) is now the first FDA-approved drug for frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome, beating mycophenolate mofetil in a randomized trial. It is also the second anti-CD20 antibody nephrologists have available for this disease — not the first. Where it fits next to rituximab, the off-label antibody most are already using, is a question this approval doesn’t answer. Sep 28, 2026Read the story For Physicians A physician in a white coat and stethoscope reviews a tablet with a patient during a clinic consultation OncologyFDA FDA Approves Oral SERD Combo for ESR1+ Breast Cancer Imlunestrant (Inluriyo) plus abemaciclib (Verzenio) is now approved for ER-positive, HER2-negative, ESR1-mutated breast cancer that progressed on prior endocrine therapy — alongside an expanded Guardant360 CDx liquid-biopsy clearance to find the patients it's for. The regimen roughly doubled progression-free survival over imlunestrant alone. What changes at the point of testing, and what still doesn't. Sep 28, 2026Read the story For Physicians A senior physician in a white coat reads clinical notes in a hospital corridor OncologyUrologyFDA FDA Approves Belzutifan-Lenvatinib Combo for Kidney Cancer Belzutifan (Welireg) plus lenvatinib (Lenvima) is now approved for advanced clear-cell renal cell carcinoma after a checkpoint inhibitor — the first regimen combining these two mechanisms in that setting. It beat cabozantinib, the trial's own comparator, on progression and response. It did not reach a significant survival benefit, and where it sits next to cabozantinib in practice is a question guidelines have not yet answered. Sep 28, 2026Read the story For Physicians A physician in a white coat and gloves checks a patient’s blood glucose with a meter during a consultation EndocrinologyFamily MedicineInternal MedicineFDA FDA Approves Onswik, Lilly’s Once-Weekly Basal Insulin Insulin efsitora alfa-gobe is the second once-weekly basal insulin cleared for U.S. adults with type 2 diabetes. It matched daily glargine and degludec on A1C across four trials, arrives with a fixed titration ladder and two pen strengths, and is not for type 1 diabetes. What changes at the prescribing desk. Sep 27, 2026Read the story For Physicians A team reviews charted figures and percentages on a whiteboard during an office planning session CardiologyPulmonologyFDA FDA Label Now Backs Early Winrevair Use in PAH HYPERION, a 320-patient trial in adults diagnosed with pulmonary arterial hypertension within the prior year, cut a composite clinical-worsening endpoint from 36.9% to 10.6% against placebo. The label now carries that evidence — but Winrevair's monitoring burden and roughly $240,000 annual cost land on referring physicians before a single dose is given. Sep 27, 2026Read the story For Physicians A professional reviews a folder of documents outdoors, lanyard and badge visible EndocrinologyFamily MedicineGeriatric MedicineFDA FDA Recalls Vitruvias Thyroid Tablets Over Superpotency One lot of Vitruvias Therapeutics’ Thyroid Tablets, USP 30 mg tested superpotent and was classified Class I — FDA’s most serious level — on 22 September 2026. The drug itself has never been FDA-approved as safe and effective, a regulatory fact that predates this recall and outlasts it. Sep 27, 2026Read the story

The 36 specialties we track

Regulatory decisions reach the clinic as new options, new limits and new warnings. This is the physician’s way into the record: what changed, by specialty.

So this is the list: the 36 specialties we track for physicians, what each one covers here, and what we have published on it. Where we have covered a specialty, its stories are here. Where we have not, it says so. The physician-facing fronts in the menu — clinical innovations, new approvals, new drugs and devices, safety updates, practice impact — open here as their pages are built.

Regulatory News tracks 36 specialties. 34 of them have published coverage on this site — 275 stories between 15 July 2026 and 5 November 2026 — and every entry below says what the specialty covers and either lists that coverage or states plainly that we have none yet. Each story behind these counts is sourced to the primary record and edited by Connor Griggs. Last updated 5 November 2026.

36 specialties · 34 with coverage

A note on how these are assigned

A specialty here describes who acts on a story, not a claim about a product’s label. A story about a cleared heart valve belongs to cardiology and cardiothoracic surgery alike; a new antibiotic to infectious disease and to the primary-care physician who will prescribe it. Coverage is matched on what a story says, and a specialty with nothing yet says so rather than borrowing a neighbour’s.

Missing one?

If a specialty belongs on this list, say so: editor@regulatorynews.com.